Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma:Towards Individualized Dosing by Yin, Anyue et al.
 
 
 University of Groningen
Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with
Adrenocortical Carcinoma
Yin, Anyue; Ettaieb, Madeleine H T; Swen, Jesse J; van Deun, Liselotte; Kerkhofs, Thomas M
A; van der Straaten, Robert J H M; Corssmit, Eleonora P M; Gelderblom, Hans; Kerstens,





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Yin, A., Ettaieb, M. H. T., Swen, J. J., van Deun, L., Kerkhofs, T. M. A., van der Straaten, R. J. H. M.,
Corssmit, E. P. M., Gelderblom, H., Kerstens, M. N., Feelders, R. A., Eekhoff, M., Timmers, H. J. L. M.,
D'Avolio, A., Cusato, J., Guchelaar, H-J., Haak, H. R., & Moes, D. J. A. R. (2020). Population
Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma:
Towards Individualized Dosing. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-020-00913-y
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the






Population Pharmacokinetic and Pharmacogenetic Analysis 
of Mitotane in Patients with Adrenocortical Carcinoma: Towards 
Individualized Dosing
Anyue Yin1,2  · Madeleine H. T. Ettaieb3  · Jesse J. Swen1,2 · Liselotte van Deun3 · Thomas M. A. Kerkhofs4 · 
Robert J. H. M. van der Straaten1 · Eleonora P. M. Corssmit5 · Hans Gelderblom6 · Michiel N. Kerstens7 · 
Richard A. Feelders8 · Marelise Eekhoff9 · Henri J. L. M. Timmers10 · Antonio D’Avolio11 · Jessica Cusato11 · 
Henk‑Jan Guchelaar1,2 · Harm R. Haak3,12,13 · Dirk Jan A. R. Moes1,2 
 
© The Author(s) 2020
Abstract
Background Mitotane is the only approved treatment for patients with adrenocortical carcinoma (ACC). A better explana-
tion for the variability in the pharmacokinetics (PK) of mitotane, and the optimization and individualization of mitotane 
treatment, is desirable for patients.
Objectives This study aims to develop a population PK (PopPK) model to characterize and predict the PK profiles of mito-
tane in patients with ACC, as well as to explore the effect of genetic variation on mitotane clearance. Ultimately, we aimed 
to facilitate mitotane dose optimization and individualization for patients with ACC.
Methods Mitotane concentration and dosing data were collected retrospectively from the medical records of patients with 
ACC taking mitotane orally and participating in the Dutch Adrenal Network. PopPK modelling analysis was performed using 
NONMEM (version 7.4.1). Genotypes of drug enzymes and transporters, patient demographic information, and clinical 
characteristics were investigated as covariates. Subsequently, simulations were performed for optimizing treatment regimens.
Results A two-compartment model with first-order absorption and elimination best described the PK data of mitotane 
collected from 48 patients. Lean body weight (LBW) and genotypes of CYP2C19*2 (rs4244285), SLCO1B3 699A>G 
(rs7311358) and SLCO1B1 571T>C (rs4149057) were found to significantly affect mitotane clearance (CL/F), which 
decreased the coefficient of variation (CV%) of the random inter-individual variability of CL/F from 67.0 to 43.0%. Fat 
amount (i.e. body weight − LBW) was found to significantly affect the central distribution volume. Simulation results indi-
cated that determining the starting dose using the developed model is beneficial in terms of shortening the period to reach 
the therapeutic target and limit the risk of toxicity. A regimen that can effectively maintain mitotane concentration within 
14–20 mg/L was established.
Conclusions A two-compartment PopPK model well-characterized mitotane PK profiles in patients with ACC. The CYP2C19 
enzyme and SLCO1B1 and SLCO1B3 transporters may play roles in mitotane disposition. The developed model is benefi-
cial in terms of optimizing mitotane treatment schedules and individualizing the initial dose for patients with ACC. Further 
validation of these findings is still required.
1 Introduction
Adrenocortical carcinoma (ACC) is a rare endocrine malig-
nancy (1 per million per year) with a poor prognosis and 
limited treatment options [1]. Mitotane, a highly lipophilic 
compound, is the only treatment approved by the US FDA 
and the European Medicines Agency for ACC [1]. Mito-
tane is developed as an orally administered treatment and 
its absorption is improved by concomitant intake of fat-rich 
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food [2]. The bioavailability of mitotane is around 35–40% 
[3]. Mitotane has a high volume of distribution and the pri-
mary distribution site is fat [3, 4]. The half-life of mitotane 
elimination ranges from 18 to 159 days, with a median of 
53 days [2, 3].
The efficacy and toxicity of mitotane are related to the 
plasma concentration [1, 3]. In order to ensure efficacy and 
avoid increased toxicity, the mitotane plasma concentration 
should be between the therapeutic range of 14 and 20 mg/L, 
which requires therapeutic drug monitoring (TDM) [1].
However, due to the large distribution volume and 
long half-life of mitotane, a long-time interval (around 
3–5 months [1]) is usually required for patients to reach the 
effective concentration [3], which limits the clinical util-
ity of mitotane. The inability to reliably predict mitotane 
plasma concentrations may result in a prolonged time to 
reach the target value, hence causing a significant delay in 
tumour treatment, or may give rise to drug toxicity. In addi-
tion, it has been demonstrated that only half of the patients 
who received a high-dose regimen for 3 months achieved 
the target [5], suggesting a demand for individualized treat-
ment and a presence of high inter-individual variability (IIV) 
in the pharmacokinetics (PK) of mitotane. Currently, the 
dosage titration is largely expert-based, making it prone to 
errors. Therefore, a tool enabling mitotane concentration 
prediction and an optimized treatment regimen for individ-
ual patients, which shortens the period required to reach the 
target concentration while limiting the toxicity, would be 
desirable for patients with ACC.
A population PK (PopPK) modelling approach with 
mixed-effect models enables quantitative characteriza-
tion and prediction of drug PK profiles for both the study 
population and individuals [6]. The development of a PopPK 
model of mitotane would be beneficial for the characteriza-
tion and understanding of mitotane PK, as well as for the 
optimization and personalization of mitotane treatment. 
Until now, two studies have performed PopPK modelling 
analysis on mitotane in patients with ACC [3, 7]; one-
compartment models were developed in these two studies. 
One study assuming a self-induced clearance and a body 
mass index (BMI) was found to be a covariate of mitotane 
distribution volume [3], while the other study identified 
the effects of triglyceride and high-density lipoprotein on 
mitotane clearance [7]. Another model-based PK study of 
mitotane developed a three-compartment model and showed 
weak correlations of age, sex, body weight, height, and body 
surface area with model parameters [8].
In order to further elucidate the variability of mitotane 
PK, it would be beneficial to explore the effect of pharmaco-
genetic polymorphisms [8]. Although the exact PK pathway 
of mitotane and the enzymes involved in mitotane metabo-
lism remain unknown [9], two studies suggested possible 
roles for cytochrome P450 (CYP) 2B6 and CYP2C9 [10, 
11]. One study demonstrated that the genotype of CYP2B6*6 
(rs3745274) was significantly correlated with mitotane 
plasma concentrations at 3 and 6 months after the initiation 
of treatment [10]. The other study showed that one patient 
with high mitotane concentration was a CYP2C9 interme-
diate metabolizer [11]. Further analysis of the relationship 
between genes encoding for PK enzymes and transporters 
and mitotane PK profiles, and incorporating these variables 
into a PopPK model, may allow better explanation of mito-
tane PK variability.
In the current study, a PopPK analysis was performed for 
mitotane in patients with ACC utilizing the retrospectively 
collected PK data. The effect of genes encoding drug absorp-
tion, distribution, metabolism, and elimination (ADME), 
patient demographic information, and clinical characteristics 
on mitotane PK were investigated as covariates. We aimed 
to develop a PopPK model to describe and predict the PK 
of mitotane in patients with ACC, as well as to explore the 
effect of genetic variation on mitotane clearance. Moreover, 
we intended to better explain mitotane PK variability using 
the developed model and to facilitate treatment optimization 
and individualization for patients with ACC.
2  Methods
2.1  Patients
Forty-nine adult patients diagnosed with ACC (≥ 18 years 
of age) who were enrolled in the Dutch Adrenal Network 
Key Points 
A two-compartment population pharmacokinetic (PK) 
model with first-order absorption and elimination was 
developed for mitotane based on PK data collected from 
48 adrenocortical carcinoma patients.
The pharmacogenetic variation of CYP2C19*2 
(rs4244285), SLCO1B3 699A>G (rs7311358) and 
SLCO1B1 571T>C (rs4149057) was found to have a 
significant effect on mitotane clearance. Fat amount, 
which was defined as the difference between total body 
weight and lean body weight, had a significant effect on 
the central distribution volume.
With the help of the model, mitotane treatment can be 
guided and optimized for individual patients. Further 
validation of the findings is warranted to confirm the 
results. .
Population PK and PG Analysis of Mitotane
Registry, had been treated with mitotane, had provided con-
sent, and had available mitotane dosing information as well 
as concentration data were included in this PopPK analysis. 
One patient was eventually excluded because of missing 
information regarding starting dose.
The study was approved by the Medical Ethical Com-
mittee of the Máxima Medical Center, Veldhoven (2015), 
and approval for the inclusion of patients in other institutes 
was obtained from the local boards. The required informed 
consents were obtained from all patients. All procedures 
performed in this study were in accordance with the ethical 
standards of the institutional Medical Ethical Committee and 
the 1964 Helsinki Declaration.
2.2  Pharmacokinetic (PK) Data
Data on mitotane plasma concentrations, including con-
centrations from routine TDM, data sampled during one 
treatment interval, and data collected after treatment dis-
continuation, as well as all mitotane dosing data, were 
collected retrospectively from patients’ medical records. 
Patients administrated mitotane orally were advised to take 
mitotane with fat-rich food. Concomitant medication infor-
mation was not included in the current analysis since the 
data were not complete. The mitotane plasma concentra-
tions were determined by a validated gas-chromatography/
mass spectrometry assay at the Department of Clinical Phar-
macy and Toxicology, Leiden University Medical Center 
(LUMC) [12]. The lower limit of quantification (LLOQ) 
was 2 mg/L. In addition, patients’ demographic informa-
tion, including age, sex, and body weight (WT) and height 
(HT) at the start of treatment, were collected. Furthermore, 
levels of serum aspartate transaminase (ASAT), alanine 
transaminase (ALAT), gamma-glutamyltransferase (γGT), 
total cholesterol, and estimated glomerular filtration rate 
(GFR; recorded as 0 if the result was ≥ 60 mL/min/1.73 m2, 
otherwise 1) were also collected in our analysis.
Lean body weight (LBW) and fat amount (FAT) were 
also calculated for each patient. LBW was estimated using 
the Boer formula [13] and FAT was obtained by subtracting 
LBW from WT.
2.3  Genotyping Method
The DNA of included patients was isolated from EDTA 
blood samples using Maxwell (Promega, Leiden, The Neth-
erlands) or MagNAPure compact (Roche, Almere, The Neth-
erlands). Genotyping of patients was performed using the 
Drug Metabolizing Enzymes and Transporters (DMET™) 
Plus array (Affymetrix UK Ltd, High Wycombe, UK), which 
contains 1936 genetic variants (1931 single nucleotide poly-
morphisms [SNPs] and 5 copy number variations [CNVs]) 
of ADME-related enzymes and transporters [14], according 
to the manufacturers’ protocol. The method has been previ-
ously described in detail [15, 16].
A preset selection was performed using the DMET™ con-
sole software that generates fully annotated marker reports 
based on a translation file as recommended by  Affymetrics® 
[17]. The reports include commonly recognized, haplotype-
based allele calls commonly cited in Medline reference stud-
ies [18–20]. The DMET™ Plus allele translation software 
produces a comprehensive genotyping report containing 
pharmacogenomic reference data on all probes. This step 
leads to the selection of 959 SNPs from the total of 1931 
SNPs present on the DMET™ platform. Subsequently, 
the SNPs that deviated from Hardy–Weinberg equilibrium 
(p < 0.0001), with a call rate below 97% or with a minor 
allele frequency (MAF) < 0.1, as well as tri-allelic SNPs and 
SNPs of genes located on the X chromosome, were excluded 
from further analysis.
2.4  Population PK Model Development
Based on the obtained mitotane concentration data, a non-
linear mixed-effects model was developed. Parameters were 
estimated using the first-order conditional estimation method 
with interaction (FOCEI) implemented in NONMEM soft-
ware version 7.4.1 (ICON Development Solutions, Ellicott 
City, MD, USA). One-, two- and three-compartment models 
with first-order absorption and first-order elimination were 
explored as the structural model. Data points below the 
LLOQ were omitted since they only contributed to 3.6% of 
the observations [21, 22].
Since the majority of collected data were trough concen-
trations, and data regarding the absorption phase were lim-
ited, the absorption rate constant (KA) was first estimated 
based on a sub-dataset containing data of the patients who 
contributed multiple data points during one treatment inter-
val at steady state. The KA estimate was then fixed to ana-
lyze the full dataset. Inter-occasion variability (IOV) was 
incorporated on apparent systemic clearance (CL/F) and 
every 200 days of treatment was defined as an occasion. In 
addition, to simplify the situation, all patients were assumed 
to receive a single dose once daily at 8:00 am, with the dose 
amount being equal to the total daily dose.
A further detailed description of the PopPK modelling 
methods is shown in Online Resource 1.
2.5  Identify Potential Correlated Single Nucleotide 
Polymorphisms and Covariate Analysis
Since knowledge regarding the relationship between mito-
tane clearance and pharmacogenetic polymorphisms is 
limited, an exploratory analysis was first performed to find 
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potential SNPs that were correlated with mitotane clear-
ance. The estimates of random IIV of CL/F ( IIViCL ) from 
the basic model and the genotyping results were utilized. 
For each SNP, when the number of patients in a minor 
homozygous group was < 4, the results of these patients 
were combined with the corresponding heterozygote group 
for the association analysis assuming a dominant allele 
effect. Additionally, when the number of patients with 
genotype results of ‘zero copy number’ or ‘possible rare 
allele’ was less than four, or when patients had ‘NoCall’ 
results, the results were not included for statistical analy-
sis. A one-way analysis of variance (ANOVA) test and a 
two-sided t test were performed using R version 3.6.1 (The 
R Foundation for Statistical Computing, Vienna, Austria) 
to evaluate the difference in IIViCL across genotype groups 
for each SNP. Selection of the test method depended on the 
number of genotype groups of each SNP after the combi-
nation. The SNPs were considered to correlate with mito-
tane clearance if the p-value was < 0.05. Correction for 
multiple testing was not performed due to the exploratory 
characteristics of the current analysis.
The identified SNPs, as well as patient demographic 
information and clinical characteristics, were considered 
in the covariate analysis. The stepwise covariate mod-
elling (SCM) function implemented with Perl-Speaks-
NONMEM (version 4.7.0) [23] was applied. Both forward 
inclusion (p < 0.05) and backward elimination processes 
(p < 0.01) were performed to identify significant covari-
ates. A more detailed description of the covariates analysis 
is shown in Online Resource 1.
2.6  Model Evaluation
The predictability and stability of the final model was 
evaluated using goodness-of-fit (GOF) plots, prediction-
corrected virtual predicted checks (pcVPC) [24], and non-
parametric bootstrap. Normalized prediction distribution 
errors (NPDEs) were also applied for evaluation. All fig-
ures were created using R (The R Foundation for Statisti-
cal Computing). A detailed description of the evaluation 
methods is shown in Online Resource 1.
2.7  Simulations for Treatment Optimization
Based on the final model, simulations were performed to 
optimize mitotane dosing regimen and starting dose deter-
mination, in order to shorten the target-reaching time while 
limiting the risk of toxicity. The simulation was performed 
for patients included in this study, as they are considered to 
be able to represent the corresponding adult patient popula-
tion. The individual parameters of each patient were used to 
simulate the ‘real’ mitotane concentrations (Csim_real) under 
each regimen. The residual errors were not considered. Dif-
ferent strategies of adjusting the dose according to Csim_real 
are shown in Fig. 1. All simulations were performed using 
R (The R Foundation for Statistical Computing) and the dif-
ferential equations were solved using the RxODE package 
(version 0.6-1) [25]. A detailed description of the regimens 
and simulation methods are shown in Online Resource 1.
On the basis of the simulated PK curves, for patients who 
originally reached the target, the mean and maximum time 
needed to reach the target ( Ttarget , the first day when Csim_real 
≥ 14 mg/L), the mean percentage of days when Csim_real was 
higher than 20 mg/L in the first 200 days ( Ptoxicity ) and the 
mean percentage of Csim_real located outside the therapeutic 
window after reaching the target ( Po.window ), were calculated 
and compared across different strategies. Ptoxicity represents 
the probability of causing toxicity in the early phase of treat-
ment, and Po.window represents the ability to maintain the 
concentration within the therapeutic window. Meanwhile, 
the median maximum and minimum Csim_real, as well as the 
range of determined starting doses, were also collected and 
evaluated. As an optimized regimen is expected to be able 
to ensure a shorter target-reaching time and well-maintain 
the concentration within the therapeutic window while not 
causing much toxicity, the optimization target was defined 
as the mean Ttarget ≤ 90 days (3 months), the mean Ptoxicity ≤ 
10%, and the mean Po.window ≤ 15%.
Using the optimized regimen, a Shiny application was 
created based on the Shiny package (version 1.4.0) and the 
RxODE package in R (The R Foundation for Statistical 
Computing) in order to perform simulation for a random 
patient and to elucidate an option of providing treatment 
advice for a new patient based on the model. A detailed 
description is shown in Online Resource 2.
3  Results
3.1  Patients and Data
Data from 48 patients with ACC (21 males and 27 females) 
were included in the PopPK analysis. The characteristics of 
patients are summarized in Table 1. Patients received mito-
tane treatment between 2002 and 2017, and the median dura-
tion of treatment was 713.5 days (range 90–2856). The total 
daily dosage ranged from 0.5 to 16 g/day and was divided 
into one to four doses. Five (two patients), six (one patient), 
and eight (one patient) daily dosages were also applied occa-
sionally. Forty-one patients reached the concentration target 
during treatment, among whom 16 patients reached the tar-
get after 150 days. In total, 914 concentration data points 
were collected from patients’ electronic hospital records, 
33 of which were below the LLOQ. The time-course of 
collected mitotane concentrations is shown in Fig. 2. Nine 
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patients contributed multiple sampling data within one 
treatment interval and 13 patients had more than one data 
point collected after treatment discontinuation. The median 
number of data points contributed by each patient was 16.5, 
ranging from 2 to 47.
3.2  The Basic Model
Based on the sub-dataset containing data from the nine 
patients with multiple sampling data within one treatment 
interval, the KA was estimated as 22.1 (/day) and 15.0 (/day) 
Fig. 1  Designed treatment regimens that were evaluated by simula-
tion. a A previously reported dosing regimen (Regimen 1), where 
the dose started as 1.5 g/day and increased up to 6 g/day in 4 days 
and continued until the next dose adjustment. The dosage was 
adjusted each time according to the monitored mitotane concentra-
tion level. b Regimens where all patients started with 2 g (Regimen 
2–2  g), 4  g (Regimen 2–4  g) or 6  g (Regimen 2–6  g) per day. The 
dosage increased by 0.5 g every 21 days until the target was reached, 
or 126  days if Csim_real < 14  mg/L. Thereafter, the dosage increased 
by 1.5  g if Csim_real < 14  mg/L, remained unchanged if 14  mg/L ≤ 
Csim_real < 18 mg/L, decreased by 1 g if 18 mg/L ≤ Csim_real < 20 mg/L, 
and decreased by 3  g if Csim_real ≥ 20  mg/L. c Regimens where 
patients started with an individualized dose that allowed Csim_pred on 
day 77 (Regimen 3–77 day), 98 (Regimen 3–98 day) or 119 (Regi-
men 3–119 day) to reach the target. The remaining dose-adjustment 
strategies were the same as Regimen 2. d Regimens where patients 
started with 4 g/day (Regimen 4) or an individualized dose (Regimen 
5) and the dosage decreased by 4 g, or 50%, if Csim_real ≥ 20 mg/L. 
The remaining dose-adjustment strategies were the same as Regi-
men 2. e Regimens where patients started with 4 g/day (Regimen 6) 
or an individualized dose (Regimen 7) and the dosage increased by 
1 g after reaching target or 126 days if Csim_real < 14 mg/L (Regimens 
6-1 and 7-1), or increased by 1  g until reaching target or 126  days 
if Csim_real < 14  mg/L (Regimens 6-2 and 7-2). The remaining dose-
adjustment strategies were the same as Regimen 2. f A regimen 
where patients started with an individualized dose that remained 
unchanged until reaching target or 105  days if Csim_real < 14  mg/L. 
The remaining dose-adjustment strategies were the same as Regi-
men 2. g A regimen where patients started with 4 g/day for the first 
21 days and the next dosage was determined that allowed Csim_ipred on 
day 98 to reach the target (Regimen 9). The remaining dose-adjust-
ment strategies were the same as Regimen 8. Csim_real simulated ‘real’ 
mitotane concentrations based on individual parameters, Csim_pred 
model predictions based on patient characteristics, Csim_ipred model 
predictions using individual parameters, i.e. incorporating the inter-
individual variability (ηIIVi) estimated based on the first monitored 
concentration
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under a one-compartment and a two-compartment model 
structure, respectively. A three-compartment model could 
not be identified, since (1) the time-course of mitotane con-
centration did not meet the characteristics of a three-com-
partment model; and (2) when running the three-compart-
ment model, the parameters were shown to be unidentifiable. 
The basic models were then developed by fitting the full 
dataset with fixed KA and incorporating IOV on CL/F. The 
relative standard error (RSE) parameter estimates of both 
two-model structures were all within the acceptable range 
(< 30%). The objective function value (OFV) of the two-
compartment model was reduced by 92.13 compared with 
that of the one-compartment model (p < 0.001, degree of 
freedom = 4), suggesting an improvement on the model fit-
ness. Therefore, the two-compartment model was ultimately 
selected for describing mitotane PK profiles in patients with 
ACC in this study. The model structure is shown in Online 
Resource 1, Fig. S1. The parameter estimates of the basic 
model are shown in Table 2. The high percentage coefficient 
of variation (CV%) of IIV for all parameters was identified, 
and the CV% of IIV for the apparent distribution rate con-
stant (Q/F) was even higher than 100%.
3.3  Pharmacogenetic Analysis
For each patient, the genotyping results of the 959 SNPs 
from the DMET™ platform were obtained. A list of these 
SNPs can be found in Online Resource 3. All SNPs were 
in Hardy–Weinberg equilibrium (p ≥ 0.0001). A flow dia-
gram of the selection of genetic variants is shown in Fig. 3. 
Eventually, 172 SNPs were included for further investiga-
tion. Among these 172 SNPs, 55 had less than four patients 
belonging to the minor homozygous group. The ‘NoCall’ 
result was reported in one patient in 19 SNPs and the ‘Pos-
sible Rare Allele’ result was reported in one patient in one 
SNP. The results of these patients were thus not included in 
the association analysis of corresponding SNPs. In contrast, 
the ‘Zero Copy Number’ result occurred in three SNPs in 8, 
24, and 24 patients, respectively. Thus, patients with a ‘Zero 
Table 1  Patient characteristics 
(n = 48)
SD standard deviation, BMI body mass index, LBW lean body weight, ASAT aspartate transaminase, ALAT 
alanine transaminase, γGT gamma-glutamyltransferase, GFR glomerular filtration rate, ENSAT European 
Network for the Study of Adrenal Tumors
a At the start of treatment
b Mean record of each patient
Characteristic Value/mean SD Range
Patient characteristics
No. of patients 48
Sex, male [n (%)] 21 (43.8)
Age,  yearsa 52.0 12.1 22.6–76.8
Weight,  kga (n = 2 no record) 80.0 15.9 52.5–120
Height,  cma (n = 5 no record) 172 10.0 154–193
BMI, kg/m2a (n = 5 no record) 27.1 4.48 18.2–38.3
LBW,  kga (n = 5 no record) 55.8 10.0 39.7–78.5
ASAT, IU/Lb (n = 1 no record) 45.15 35.3 16–185
ALAT, IU/Lb (n = 1 no record) 42.68 35.6 9–197
γGT, IU/Lb (n = 1 no record) 278.70 215.9 55–898
GFR, > 50% of records were normal [n (%)] (n = 7 no record) 39 (95.1)
Cholesterol, mmol/Lb (n = 11 no record) 6.54 1.56 3.6–11.6
Disease characteristics [n (%)]
ENSAT I, patients 2 (4.2)
ENSAT II, patients 19 (39.6)
ENSAT III, patients 10 (20.8)
ENSAT IV, patients 17 (35.4)
Target-reaching characteristics
No. of patients who reached the target 41
> 150 days [n (%)] 16 (39.0)
≤ 90 days [n (%)] 19 (46.3)
Target-reaching time, days 142 113.9 24–579
Duration of treatment, days 742 553.2 90–2856
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Fig. 2  Mitotane concentra-
tion–time curve collected from 
patients on the logarithmic 
scale. Inserts show the data 
during the first 600 days of 
treatment
Table 2  Parameter estimates of both the basic and final models
SNP1 CYP2C19*2 (rs4244285), SNP2 SLCO1B3 699A>G (rs7311358), SNP3 SLCO1B1 571T>C (rs4149057), LBW lean body weight, FAT fat 
amount, RSE relative standard error, CV coefficient of variation, IIV interindividual variability, IOV interoccasion variability, PRO proportional resid-
ual error, ADD additive residual error, CL/F apparent systemic clearance, KA absorption rate constant, Vc/F apparent distribution volume of the cen-
tral compartment, Vp/F apparent distribution volume of the peripheral compartment, Q/F apparent distribution rate constant, CI confidence interval
a CL∕F = CL∕F
t










c Every 200 days of dosing was defined as an occasion














KA (/day) 15.0 fixed – – 15.0 fixed – – 15 –
CL/F (L/day)a 217 (11) 67.0 [8] 30.5 298 (13) 43.0 [16] 31.6 281.6 200.5–398.4
CL_SNP1 (GA/
AA)
– – – 0.551 (15) – – 0.573 0.385–0.881
CL_SNP2 (AG/
GG)
– – – 0.601 (19) – – 0.613 0.419–0.949
CL_SNP3 (CC) – – – 0.753 (10) – – 0.784 0.550–1.07
CL_SNP3 (TT) – – – 2.49 (29) – – 2.67 0.991–6.16
CL_LBW (power) – – – 1.10 (16) – – 1.07 0.205–2.13
Vc/F (L)b 4790 (20) 68.1 [53] – 6210 (18) 47.2 [55] – 6795 3281–10,752
Vc_FAT (power) – – – 1.22 (19) – – 1.29 0.450–2.18
Vp/F (L) 19,300 (13) 76.9 [17] – 18,100 (12) 88.8 [15] – 17882 11,341–25,709
Q/F (/day) 1100 (21) 102 [34] – 883 (20) 97.3 [34] – 785.4 337.4–1502
Residual errors
PRO (CV%) 16.6 (7) – – 16.6 (6) – – 16.8 14.2–18.9
ADD (mg/L) 0.931 (28) – – 0.920 (17) – – 0.871 0.373–1.384
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Copy Number’ were treated as a different genotype group in 
the association analysis of these three SNPs.
Finally, the result of the association test showed that 
11 SNPs, as shown in Online Resource  1, Table  S1, 
were potentially related to mitotane clearance (p ≤ 0.05). 
Among these 11 SNPs, the genotyping results of CYP2C18 
1154C > T (rs2281891) and CYP2C19*2 (rs4244285) 
were shown to be 100% in linkage disequilibrium in our 
dataset, which was the same as the genotyping results of 
SLCO1B3 334G>T (rs4149117), 699A>G (rs7311358), 
and 1557G>A (rs2053098) and that of the three SNPs 
located on VKORC1 (283 + 124G>C, 174-136C>T, and 
-1639G>A). The results of the 11 identified SNPs were 
subsequently combined into the full dataset for stepwise 
covariate analysis.
3.4  The Final Model
The parameter estimates of the final model are shown 
in Table  2. The CYP2C19*2 (rs4244285), SLCO1B3 
699A>G (rs7311358) and SLCO1B1 571T>C (rs4149057) 
genotypes, and LBW at the start of treatment, with power 
relation, were found to have a significant effect on the 
CL/F of mitotane (Table 2). Carrying the ‘A’ variant in 
CYP2C19*2 reduced the CL/F by 44.9%, and carrying 
‘G’ variant in SLCO1B3 699A>G resulted in a 39.9% 
reduction in CL/F (Table 2). As for SLCO1B1 571T>C, 
the CL/F of patients carrying one ‘C’ variant decreased 
to 40.2% that of wild-type patients, while the CL/F of 
patients carrying two ‘C’ variants decreased to 30.2%. 
The distribution of IIViCL derived from the basic model 
in each genotype group of the above three SNPs is shown 
in Online Resource 1, Fig. S2. In addition, FAT at the 
start of treatment with power relation was found to sig-
nificantly influence the apparent distribution volume of the 
central compartment (Vc/F). The inclusion of these covari-
ates decreased the CV% of CL/F and Vc/F from 67.0% 
and 68.1% to 43.0% and 47.2%, respectively. Overall, the 
parameter estimates were shown to be in good agreement 
with the bootstrap results (Table 2).
The GOF plots (Fig. 4) show that the individual predic-
tions of the final model are in good accordance with the 
observations, while the population predictions are slightly 
deviated from the observations. The conditional weighted 
residual errors (CWRES) randomly distributed around 
zero, without obvious trends over time or across popu-
lation predictions. The pcVPC plot (Fig. 5) shows that 
the 5th, 50th, and 95th percentiles of prediction-corrected 
concentrations can be mostly adequately covered by the 
95% confidence interval (CI) of the corresponding per-
centiles of simulations, although a few large prediction-
corrected concentrations are present. The NPDE results 
are shown in Online Resource 1, Fig. S3.
3.5  Simulation Results
The simulation results of different regimens in included 
patients who originally reached the target (n = 41) are sum-
marized in Table 3.
The previously suggested high-dose regimen (Regimen 
1) resulted in the lowest Ttarget but the highest Ptoxicity . The 
Csim_real can also not be well-maintained within the thera-
peutic range.
As for the newly designed strategies, if all patients started 
with the same dosage (Regimen 2–2 g, 2–4 g and 2–6 g), 
the increase in the starting dosage reduced the Ttarget but 
increased Ptoxicity and weakened the ability of maintaining 
Csim_real within the therapeutic range. When determining the 
starting dose individually (Regimen 3–77 day, 3–98 day and 
3–119 day), Regimen 3–98 day fulfilled the optimization 
target and resulted in a lower Ttarget but higher Ptoxicity and 
Po.window compared with Regimen 2–4 g. The range of deter-
mined starting dose was in accordance with what is currently 
recommended (Table 3) [26].
Fig. 3  Selection of the genetic variants. Excl. excluding, Ch X chro-
mosome X, DMET™ Drug Metabolizing Enzymes and Transport-
ers, CNVs copy number variations, SNPs single nucleotide polymor-
phisms
Population PK and PG Analysis of Mitotane
Compared with Regimens 2–4 g and 3–98 day, increasing 
the dose reduction amount to 4 g when Csim_real > 20 mg/L 
reduced the Ptoxicity and Po.window , whereas setting a 50% 
deduction when Csim_real > 20 mg/L reduced the Po.window 
but increased the Ptoxicity (Regimens 4 and 5). Both of these 
changes did not affect Ttarget . In contrast, when adjusting the 
dose change amount when Csim_real < 14 mg/L, the evaluated 
regimens did not provide better results (Regimens 6 and 7).
Regimen 8, where a constant starting dose determined 
by the model was applied, provided generally better results 
compared with starting with 4 g/day for all patients (Regi-
men 2–4 g) in terms of Ttarget , Ptoxicity , and the ability to 
maintain concentration within the therapeutic range. The 
suggested starting dose range (3–7 g, median 5 g) was 
slightly beyond the current recommended range but was 
considered to be acceptable. In comparison, when determin-
ing a constant dose using individual PK parameters (incor-
porating IIV estimates) [Regimen 9], the Po.window and maxi-
mum Ttarget decreased. Although Ptoxicity increased, it was still 
low enough. The suggested doses under Regimen 9 were 
relatively higher (3–10 g) since IIV was taken into account.
Overall, Regimens 2–4  g, 3–98  day, 4–(−  4  g), 
4–(− 50%), 5–(− 4 g), 7-1, 8, and 9 fulfilled the optimization 
target. The individualized starting dose resulted in a lower 
Ttarget but higher Ptoxicity compared with the fixed starting 
dose. Regimens 3–98 day and 5–(− 4 g) provided the low-
est mean Ttarget , while regimen 5–(− 4 g) resulted in lower 
Ptoxicity . Regimen 8 provided the lowest Ptoxicity and Regimen 
9 provided the lowest maximum Ttarget and mean Po.window . 
Based on these results, Regimen 5–(− 4 g) and Regimen 8 
Fig. 4  Goodness-of-fit plots of the final population pharmacokinetic 
model of mitotane in patients with adrenocortical carcinoma, includ-
ing observations versus a population predictions and b individual pre-
dictions, and CWRES versus c time and d populations predictions. 
The black dotted lines represent y = x (a, b) and y = 0 (c, d), and the 
black dashed lines represent the corresponding LOESS regressions. 
CWRES conditional weighted residual errors, LOESS locally esti-
mated scatterplot smoothing
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Fig. 5  Prediction-corrected 
visual predictive check plot of 
the final model on the logarith-
mic scale. Black dashed lines 
represent the 50th, 95th and 5th 
percentiles of the prediction-
corrected observations; light-
grey shading represents the 95% 
confidence interval of the 95th 
and 5th percentiles of the simu-
lations; and dark-grey shading 
represents the 95% confidence 
interval of the 50th percentiles 
of the simulations
Table 3  Simulation results of different treatment regimens for included patients who originally reached the target (n = 41)
Ttarget target reaching time (the day when simulated mitotane concentration ≥ 14 mg/L), Ptoxicity percentage of days when simulated mitotane 
concentrations were higher than the upper limit of mitotane therapeutic window (20 mg/L) in the first 200 days, Po.window percentage of simulated 
mitotane concentrations located outside the therapeutic window after reaching the target, max maximum, min minimum, * indicates the regimen 
fulfills the optimization target, Csim_real simulated ‘real’ mitotane concentrations based on individual parameters
Regimen (Fig. 1) Mean Ttarget (day) Max Ttarget 
(day)






1 54.22 125 23.6 18.35 22.3/13.11 –
2-2 g 133.98 236 4.16 12.6 20.65/13.14 2
2-4 g 89.8 182 7.01 13.15 20.90/13.20 4 *
2-6 g 60.61 149 13.85 15.13 21.13/13.09 6
3-77 day 73 173 10.63 12.7 21.07/13.29 3.5–7
3-98 day 85.07 182 9.26 14.35 21.03/13.16 3–6 *
3-119 day 97.9 191 6.44 12.22 20.96/13.21 2.5–5
4-(-4 g) 89.8 182 5.96 12.66 20.91/13.22 4 *
4-50% 89.8 182 8.82 12.37 20.91/13.22 4 *
5-(-4 g) 85.07 182 7.92 13.01 20.84/13.14 3–6 *
5–50% 85.07 182 11.13 12.21 20.84/13.22 3–6
6-1 91.12 194 6.61 13.37 20.84/12.91 4
6-2 74.32 151 14.34 16.26 21.57/13.02 4
7-1 86.12 194 8.52 14.69 21.03/12.96 3–6 *
7-2 80.27 160 14 15.53 21.46/12.87 2.5–5
8 87.85 191 5.05 11.26 20.34/13.30 3.5–7 *
9 87.8 161 5.56 10.72 20.33/13.09 3–10 *
Population PK and PG Analysis of Mitotane
were considered to be more beneficial, while Regimen 9 
could also be applied, considering the patients’ tolerance to 
the level of dose increase.
The Shiny app was established based on the final model, 
and the treatment strategy 5–(− 4 g) was applied since this 
regimen provided the lowest mean Ttarget . A reduced model 
where the effect of pharmacogenetic variation was not 
included was also built in to serve as an alternative option 
for patients when genotyping results were not available. The 
results are shown in Online Resource 2.
4  Discussion
In the current study, a two-compartment PopPK model 
was developed that adequately described the PK profile of 
mitotane in patients with ACC. The covariates identified 
explained 24% and 20.9% of random variability in mitotane 
clearance and distribution volume, respectively. As mitotane 
distributes in most body tissues, predominantly in the fat [1], 
the two-compartment model structure is considered to also 
be in line with the PK characteristics of mitotane, although 
the wide 95% CI of the Q/F parameter still indicates uncer-
tainty in the estimation. A three-compartment model struc-
ture, which has been previously applied on mitotane [8], 
could not be identified in this study as the time-course of 
mitotane concentration did not meet the characteristics of a 
three-compartment model and parameter estimates for the 
three-compartment model were found to be unidentifiable.
Because of the limited data in the absorption phase, KA 
was first estimated based on a sub-dataset and then fixed to 
analyze the full dataset. Precise KA estimation was unidenti-
fiable if estimating based on the full dataset. The estimates of 
Vc/F and Vp/F were relatively large, which is in accordance 
with previous reports and the fact that mitotane distributes 
in many body tissues [1, 3]. The separate effects of LBW 
and FAT on mitotane distribution volumes were of interest 
in this study as they are more realistic covariates physiologi-
cally [3, 4]. As a result, FAT was found to be a significant 
covariate on the Vc/F. The estimated half-life of mitotane in 
the included patients ranged from 16.4 to 700.6 days, with 
a median of 101.5 days. This range is wider than what has 
been previously reported [1, 2], which may be explained by 
the larger number of patients included in the current study 
than in the original study [2]. Incorporating IOV on CL/F in 
the current study explained the intrasubject variability. The 
estimates of IOV indicate an overall increasing clearance 
during the first 500 days, followed by a decrease thereafter 
(Online Resource 1, Fig. S4). This dynamic indicates that 
a self-induction in mitotane clearance, which has been sug-
gested previously [3], may exist temporarily.
For the first time, the current study explored and quan-
tified the potential effect of pharmacogenetic variation on 
mitotane clearance in patients with ACC. Due to the lack of 
knowledge regarding the PK pathway of mitotane, a wide 
range of SNPs from the DMET™ Plus array were consid-
ered. However, because of the limited number of patients, it 
was decided to focus on the SNPs with known functionality 
by adopting a preset selection [17], although an exploratory 
analysis based on all genetic variants from the DMET™ 
Plus array was also performed. The flow diagram of the SNP 
selection and the nine additional SNPs that are potentially 
correlated to mitotane clearance if the preset selection was 
not considered are shown in Online Resource 1, Table S2 
and Fig. S5. Genes located on the X chromosome were 
excluded since only the general influence of sex on mitotane 
PK was considered.
Eventually, three SNPs, i.e. CYP2C19*2 (rs4244285), 
SLCO1B3 699A>G (rs7311358) and SLCO1B1 571T>C 
(rs4149057), were included in the final model and were con-
sidered as the pharmacogenetic polymorphisms that should 
be considered for mitotane dose selection. This result also 
suggests that the CYP2C19 enzyme and SLCO1B3 and 
SLCO1B1 transporters for drug uptake in the liver might be 
involved in the mitotane PK pathways, but further confirma-
tion is required.
In fact, in our dataset, CYP2C19*2 was in 100% link-
age disequilibrium with CYP2C18 1154C>T (rs2281891), 
which was the same as SLCO1B3 699A>G with 
SLCO1B3 334G>T (rs4149117) and SLCO1B3 1557G>A 
(rs2053098). Comparable high linkage disequilibrium 
was also found in 1000 Genomes CEU population (Utah 
residents with Northern and Western European ancestry). 
Compared with CYP2C18 1154C>T, for which no suf-
ficient evidence has been found regarding the effect on 
the drug PK, the ‘A’ variant of CYP2C19*2 is known to 
be a nonfunctioning variant and has been demonstrated to 
decrease the activity of CYP2C19 [27, 28]. Similarly, the 
variants of SLCO1B3 699A>G with SLCO1B3 334G>T 
have been reported to be associated with a decrease in drug 
clearance, and SLCO1B3 699A>G has a stronger level of 
clinical annotations [29, 30]. Therefore, CYP2C19*2 and 
SLCO1B3 699A>G were included in the final model.
CYP2B6*6, which has been reported to be related to mito-
tane plasma concentrations detected at 3 and 6 months [10], 
was not found to have a significant effect on mitotane clear-
ance in the current study. Among the five SNPs located on 
CYP2B6 that were included in the association analysis, none 
were significantly related to mitotane clearance (p > 0.05). 
This discrepancy may be due to the much longer observation 
period in the present study. One SNP located on CYP2C9, 
CYP2C9*2 (rs1799853), was also not found to be signifi-
cant; however, the evidence of the involvement of CYP2C9 
is in fact insufficient.
The predictability and stability of the final model were 
confirmed to be acceptable. In the pcVPC plot, a few 
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prediction-corrected concentrations are inadequately covered 
by the simulations. A possible explanation is that the observa-
tions at corresponding time points are from a single patient 
and the population prediction of this patient is much smaller 
than real observations. The deviation of population predic-
tions from observations can also be seen in the GOF plots. 
Patients’ adherence and other unknown factors may also intro-
duce additional bias. Identification of additional covariates, 
such as the effect of co-medication and food intake, might 
improve the population predictions.
Based on the final PopPK model, several mitotane treat-
ment strategies were designed and evaluated by simulations. 
A regimen with a bolus dose followed by a maintenance dose 
was not considered as this regimen requires a high dosage, 
which is not tolerable for some patients. Among the regimens 
that fulfilled the optimization target, applying the individual 
starting dose determined by the model was demonstrated to 
shorten the time to achieve the therapeutic window compared 
with starting with a fixed dose for all patients. Under the 
setting of individualized starting dose, the regimens with a 
stepwise increasing dose at start required less time to reach 
the therapeutic target, while the regimen with a constant 
starting dose demonstrated the lowest risk of having toxicity. 
The determined individual starting dose was also acceptable. 
In addition, the newly designed dose-adjustment strategies 
were able to satisfactorily keep the mitotane concentrations 
within the therapeutic range. Therefore, determining the 
starting dose using the developed model is considered to 
be most beneficial in terms of shortening the time to reach 
the therapeutic target and limit the risk of toxicity. However, 
due to the fact that a shorter Ttarget is normally paired with a 
higher Ptoxicity , it is suggested to consider, based on a patient’s 
condition, whether the increased risk of having toxicity can 
be tolerated in order to gain the benefit of a shorter time to 
reach the therapeutic target when selecting a dosing regimen.
Obtaining individual parameters based on one (or more) 
TDM result with the PopPK model, and determining the 
dose amount accordingly, can also decrease the risk of toxic-
ity while providing a satisfactory target reaching time; thus, 
this is also a promising strategy. However, patients’ tolerance 
to the high level of dose increase needs to be considered 
when applying this strategy. This method can also be useful 
to estimate an adequate dose for the drug concentration level 
maintenance after reaching the therapeutic window, thereby 
decreasing the frequency of dose adjustment.
Simulation results also indicate that in order to reduce the 
risk of having toxicity and to effectively maintain mitotane 
concentration within the therapeutic range, a better strategy 
is to set the concentration boundary of dose decreases at 
18 mg/L instead of 20 mg/L. This early dose adjustment 
takes into consideration the 7-day period when the monitor-
ing result is unknown and the dose is not adjusted. The con-
centration boundary of dose increases needs to be 14 mg/L 
since it affects the adequacy of maintaining the plasma con-
centration above 14 mg/L. The frequency of TDM was set 
at once every 21 days, as suggested by the guideline in the 
simulation. If TDM is performed less frequently, a larger 
dose change step will be required.
The current study has some limitations. First, the small 
number of patients included in this study and the explora-
tory characteristics of this analysis may influence the power 
of covariate analysis, especially for pharmacogenetic analy-
sis. However, as the dataset consisted of concentrations on 
different occasions for each patient, which enabled differen-
tiation between IIV and intrasubject variability (i.e. IOV) in 
clearance, the certainty of the possible genotype effect on 
clearance, which is more likely to be covered by IIV since 
genotype is a constant factor in patients, was increased. None-
theless, further validation with an external dataset to replicate 
the findings is warranted to confirm the identified associations 
and to translate the findings into a clinical recommendation. 
However, since ACC is a very rare disease (1 per million per 
year), the collection of another comparable or even larger 
dataset will be challenging. Therefore, an in vitro assay might 
be more feasible in future studies to substantiate the activity 
of the suggested enzymes in mitotane PK. Second, the model 
lacks a strong ability to accurately predict high concentrations 
(e.g., peak concentrations) due to the limited data input in the 
absorption and distribution phase. Furthermore, the accuracy 
of parameter estimates may be affected by our simplification 
of multiple daily dosing to a single dose. However, the pre-
diction of mitotane trough concentrations and the suggestion 
of daily dose based on the model will not be significantly 
affected. Therefore, we believe this model is still fit for the 
current application. Third, the impact of coadministrated 
drugs and food intake on mitotane PK was not taken into 
account in this study due to the lack of data.
5  Conclusions
The current study presents a two-compartment PopPK model 
that well-characterizes mitotane PK profiles in patients with 
ACC. The polymorphisms of CYP2C19*2 (rs4244285), 
SLCO1B3 699G>A (rs7311358) and SLCO1B1 571T>C 
(rs4149057) were found to be correlated to mitotane PK. Fur-
ther external or in vitro evaluation is suggested to confirm the 
results. Moreover, optimized mitotane treatment schedules for 
patients with ACC were identified by simulation and the devel-
oped model can be of help to individualize the initial dose. 
These strategies should be confirmed in a prospective study.
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